Business Wire

One Banana, the Better Banana Co., Presents Corporate Sustainability Report

Share

One Banana publishes its sixth Sustainability Report, which presents the results of projects, programs, and good practices that have contributed to the success of the operations and further its efforts to become a world-class company in quality, productivity, and profitability. See the One Banana Sustainability Report here.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200620005027/en/

We truly believe that One Banana Makes a Difference. With the publication of its sixth Sustainability Report, One Banana reassures it’s commitment to contribute to a better world, continue and improve its position in the market, maintain competitiveness, and continue to pioneer the highest standards in the industry. (Photo: Business Wire)

We truly believe that One Banana Makes a Difference. With the publication of its sixth Sustainability Report, One Banana reassures it’s commitment to contribute to a better world, continue and improve its position in the market, maintain competitiveness, and continue to pioneer the highest standards in the industry. (Photo: Business Wire)

One Banana aims to generate value and balance in economic growth, conservation of natural resources, and the welfare of all its stakeholders. Robert Adams, President of One Banana, said, “We are proud to be a third-generation, family-owned, vertically integrated company. All of our actions are performed with the commitment to preserve our resources and responsibly produce the highest quality bananas and ingredients from our own farms.

With a business model based on a Corporate Sustainability Strategy, One Banana has implemented actions based on initiatives proposed by the United Nations, such as the Sustainable Development Goals and the Ten Principles of Global Compact.

Some notable outstanding results for 2019 were:

  • About 20,000 hectares were conserved due to participation in landscape sustainability projects and forest area conservation programs at our plantations.
  • Innovation and investment in new product lines. The company’s focus on Banana Ingredients and farm productivity allows us to close the loop on banana surplus from farms into the production of the highest quality Puree, Flakes, and Powders.
  • Between 2014 and 2019, more than 31,000 patients including workers and community members received medical care at our Medical Center established in the southwestern region of Guatemala, as part of our Comprehensive Health Project.

The company continues to develop the highest quality standards and compliance with international certifications, basing its performance on the best agro-industrial practices and the implementation of a Corporate Sustainability Strategy at every level of the operation.

About ONE Banana:

ONE Banana is a family owned sustainable grower, shipper and distributor of tropical fruit with operations in the United States, Guatemala, Europe, Peru, and Ecuador. It has emerged as a leader in socially responsible and environmentally sustainable farming. For more information please visit: https://www.onebananas.com

Contact information

Javier Aguirre
Corporate Director
info@onebananas.com
(502) 2420-9600

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 12:55:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 12:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 07:00:00 CESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline ® Autogel ® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 07:00:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel®(lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatmen